Tolerability of intramuscular and intradermal delivery by CELLECTRA® adaptive constant current electroporation device in healthy volunteers

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 10, 2013, Pages 2246-2252

  Diehl, Malissa C ^a   Lee, Jessica C ^a   Daniels, Stephen E ^b   Tebas, Pablo ^c   Khan, Amir S ^a   Giffear, Mary ^a   Sardesai, Niranjan Y ^a   Bagarazzi, Mark L ^a  

^a Inovio Pharmaceuticals   (United States)

^b Premier Research   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Electroporation; Intradermal; Intramuscular; Vaccination; Visual analog scale

Indexed keywords

DNA VACCINE;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COUGHING; DNA IMMUNIZATION; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY DEVICE; DRUG EFFICACY; DRUG TOLERABILITY; DYSKINESIA; ELECTROPORATION; ELECTROPORATION DEVICE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMATOMA; HUMAN; HUMAN EXPERIMENT; INJECTION SITE BURNING; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; INJECTION SITE WARMTH; MALE; MYALGIA; NEUROLOGIC DISEASE; NORMAL HUMAN; PAIN ASSESSMENT; PATIENT SAFETY; RESPIRATORY TRACT DISEASE; VISUAL ANALOG SCALE;

ELECTROPORATION; INTRADERMAL; INTRAMUSCULAR; VACCINATION; VISUAL ANALOG SCALE;

ADULT; ELECTROPORATION; FEMALE; HEALTHY VOLUNTEERS; HUMANS; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PAIN; SEVERITY OF ILLNESS INDEX; VACCINATION; VACCINES, DNA; YOUNG ADULT;

EID: 84885161878     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.24702     Document Type: Article

References (32)

1. Sardesai NY, Weiner DB. Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol 2011;23:421-9; PMID:21530212; http://dx.doi.org/10.1016/j.coi.2011.03.008
2. Mir LM. Therapeutic perspectives of in vivo cell electro permeabilization. Bioelectro chemistry 2001;53:1-10; PMID:11206915; http://dx.doi.org/10.1016/S0302-4598 (00) 00112-4
3. Bodles-Brakhop AM, Heller R, Draghia-Akli R. Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments. Mol Ther 2009;17:585-92; PMID:19223870; http://dx. doi.org/10.103 8/mt.2009.5
4. Cemazar M, Sersa G. Electro transfer of therapeutic molecules into tissues. Curr Opin Mol Ther 2007;9:554-62; PMID:18041666
5. Van Drunen Littel-Van Den Hurk S, Hannaman D. Electroporation for DNA immunization: clinical application. Expert Rev Vaccines 2010;9:503-17; PMID:20450325; http://dx. doi.org/10.1586/erv. 10.42
6. Dupuis M, Denis-Mize K, Woo C, Goldbeck C, Selby MJ, Chen M, et al. Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. J Immunol 2000;165:2850-8; PMID: 10946318
7. Babiuk S, Baca-Estrada ME, Foldvari M, Middleton DM, Rabussay D, Widera G, et al. Increased gene expression and inflammatory cell infiltration caused by electroporation are both important for improving the efficacy of DNA vaccines. J Biotechnol 2004;110:1-10; PMID:15099900; http://dx.doi. Org/10.1016/j. jbiotec.2004.01.015
8. Khan AS, Pope MA, Draghia-Akli R. Highly efficient constant-current electroporation increases in vivo plasmid expression. DNA Cell Biol 2005;24:810-8; PMID:16332178; http://dx.doi.org/10.1089/dna.2005.24.810
9. Draghia-Akli R, Smith LC. Electrokinetic Enhancement of Plasmid Delivery In Vivo. In: Templeton NS, Lasic DD (eds). Gene Therapy-Therapeutic Mechanisms and Strategies. New York: Marcel Dekker, Inc., 2003:245-263.
10. Hirao LA, Wu L, Khan AS, Satishchandran A, Draghia-Akli R, Weiner DB. Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine 2008;26:440-8; PMID: 18082294; http://dx.doi.org/10.1016/j.vaccine.2007.10.041
11. Tobin DJ. Biochemistry of human skin-our brain on the outside. Chem Soc Rev 2006;35:52-67; PMID: 16365642; http://dx.doi.org/10.1039/b505793k
12. Martinon F, Kaldma K, Sikut R, Culina S, Romain G, Tuomela M, et al. Persistent immune responses induced by a human immunodeficiency virus DNA vaccine delivered in association with electroporation in the skin of nonhuman primates. Hum Gene Ther 2009;20:1291-307; PMID:19627235; http://dx.doi.org/10. 1089/hum.2009.044
13. Brave A, Nystrom S, Roos AK, Applequist SE. Plasmid DNA vaccination using skin electroporation promotes poly-functional CD4 T-cell responses. Immunol Cell Biol 2011;89:492-6; PMID:20838412; http://dx.doi.org/10.1038/icb.2010.109
14. Saade F, Petrovsky N. Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines 2012;11:189-209; PMID:22309668; http://dx.doi.org/10.1586/ erv.11.188
15. Paul-Dauphin A, Guillemin F, Virion JM, Briamjon S. Bias and precision in visual analogue scales: a randomized controlled trial. Am J Epidemiol 1999;150:1117-27; PMID: 10568628; http://dx.doi.org/10.1093/oxfordjournals.aje. a00 99 37
16. Grant S, Aitchison T, Henderson E, Christie J, Zare S, McMurray J, et al. A comparison of the reproducibility and the sensitivity to change of visual analogue scales, Borg scales, and Likert scales in normal subjects during submaximal exercise. Chest 1999;116:1208-17; PMID: 10559077; http://dx.doi.org/10.1378/chest. 116.5.1208
17. Wallace M, Evans B, Woods S, Mogg R, Zhang L, Finnefrock AC, et al. Tolerability of two sequential electroporation treatments using MedPulser DNA delivery system (DDS) in healthy adults. Mol Ther 2009;17:922-8; PMID: 19277016; http://dx.doi.org/10.1038/mt.2009.27
18. ™ clinical epidermal electroporation system in healthy adults. Mol Ther 2012;20:214-20; PMID:22068424; http://dx.doi.org/10.1038/mt.2011.235
19. Rizzuto G, Cappelletti M, Maione D, Savino R, Lazzaro D, Costa P, et al. Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation. Proc Natl Acad Sci U S A 1999;96:6417-22; PMID: 10339602; http://dx.doi.org/10.1073/pnas.96.11.6417
20. Hartikka J, Sukhu L, Buchner C, Hazard D, Bozoukova V, Margalith M, et al. Electroporation-facilitated delivery of plasmid DNA in skeletal muscle: plasmid dependence of muscle damage and effect of poloxamer 188. Mol Ther 2001;4:407-15; PMID: 11708877; http://dx.doi.org/10.1006/mthe.2001.0483
21. Ulmer JB, Wahren B, Liu MA. Gene-based vaccines: recent technical and clinical advances. Trends Mol Med 2006;12:216-22; PMID: 16621717; http://dx.doi.org/10.1016/j.molmed.2006.03.007
22. Murtaugh MP, Foss DL. Inflammatory cytokines and antigen presenting cell activation. Vet Immunol Immunopathol 2002;87:109-21; PMID: 12072225; http://dx.doi.org/10.1016/S0165-2427 (02) 00042-9
23. Peachman KK, Rao M, Alving CR. Immunization with DNA through the skin. Methods 2003;31:232-42; PMID:14511956; http://dx.doi.org/10.1016/S1046-2023 (03) 00137-3
24. Roos AK, Moreno S, Leder C, Pavlenko M, King A, Pisa P. Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation. Mol Ther 2006;13:320-7; PMID:16185933; http://dx.doi. Org/10.1016/j.ymthe.2005.08.005
25. Liu J, Kjeken R, Mathiesen I, Barouch DH. Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation. J Virol 2008;82:5643-9; PMID:18353952; http://dx.doi.org/10. 1128/JVI.02564-07
26. Rosati M, Valentin A, Jalah R, Patel V, Von Gegerfelt A, Bergamaschi C, et al. Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation. Vaccine 2008;26:5223-9; PMID: 18468743; http://dx.doi.org/l 0.1016/j.vaccine.2008.03.090
27. Rosati M, Bergamaschi C, Valentin A, Kulkarni V, Jalah R, Alicea C, et al. DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge. Proc Natl Acad Sci U S A 2009;106:15831-6; PMID: 19717425; http://dx.doi.org/10.1073/pnas. 0902628106
28. Gronevik E, Mathiesen I, Lomo T. Early events of electroporation-mediated intramuscular DNA vaccination potentiate Thl-directed immune responses. J Gene Med 2005;7:1246-54; PMID: 15822067; http://dx. doi.org/10.1002/jgm. 760
29. Selby M, Goldbeck C, Pertile T, Walsh R, Ulmer J. Enhancement of DNA vaccine potency by electroporation in vivo. J Biotechnol 2000;83:147-52; PMID: 11000470; http://dx.doi.org/10.1016/S0168-1656 (00) 00308-4
30. Tollefsen S, Tjelle T, Schneider J, Harboe M, Wiker H, Hewinson G, et al. Improved cellular and humoral immune responses against Mycobacterium tuberculosis antigens after intramuscular DNA immunisation combined with muscle electroporation. Vaccine 2002;20:3370-8; PMID:12213407; http://dx.doi.org/10. 1016/S0264-4l0X (02) 00289-X
31. Phase I of Human Papillomavirus (HPV) DNA Plasmid. (VGX-3100) + Electroporation for CIN 2 or 3. http://www.clinicaltrials.gov/ct2/show/ NCT00685412.
32. Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid. (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100.